EG Capital Group

Presto is a leading provider of labor automation technology, founded in 2008 at M.I.T. and headquartered in Silicon Valley, California. The company specializes in integrating advanced digital solutions into the hospitality industry, utilizing voice, vision, and touch technologies to enhance customer experiences and streamline operations. With over 250,000 systems deployed, Presto serves many of the top 20 restaurant chains in the U.S. Its innovative artificial intelligence solutions focus on automating speech recognition specifically for drive-thru operations, helping clients address labor shortages and generate new revenue streams.

C4 Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutic candidates aimed at targeting and eliminating disease-causing proteins for the treatment of cancer, neurodegenerative diseases, and other conditions. The company's lead product candidate, CFT7455, is an orally bioavailable degrader targeting IKZF1/3, designed to treat multiple myeloma and various lymphomas. Additionally, C4 Therapeutics is advancing CFT8634, which targets BRD9 for synovial sarcoma and SMARCB1-deleted solid tumors, as well as programs targeting BRAF V600E and RET for genetically defined resistant solid tumors. The company employs its proprietary Degronimid platform, which utilizes small molecule binders to flag harmful proteins for degradation by the cellular proteasome system, allowing for the potential treatment of previously undruggable targets. Founded in 2015 and headquartered in Watertown, Massachusetts, C4 Therapeutics engages in strategic collaborations to enhance its research and development efforts.